These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23684111)

  • 1. [Definitive chemoradiotherapy for esophageal cancer: 66Gy versus 50Gy, a retrospective study].
    Clavier JB; Antoni D; Atlani D; Ben Abdelghani M; Schumacher C; Salze P; Noël G
    Cancer Radiother; 2013 Jun; 17(3):221-8. PubMed ID: 23684111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Esophageal cancer: outcome according to therapeutic strategy].
    Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
    Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
    Clavier JB; Antoni D; Atlani D; Ben Abdelghani M; Schumacher C; Dufour P; Kurtz JE; Noel G
    Dis Esophagus; 2014 Aug; 27(6):560-7. PubMed ID: 23106980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma.
    Reid TD; Davies IL; Mason J; Roberts SA; Crosby TD; Lewis WG
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):617-24. PubMed ID: 22386923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
    Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The multimodality therapy of advanced inoperable esophageal carcinoma. A retrospective analysis].
    Mücke R; Ziegler PG; Libera T; Klautke G; Fietkau R
    Strahlenther Onkol; 2000 Aug; 176(8):350-5. PubMed ID: 10987017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    Park JW; Kim JH; Choi EK; Lee SW; Yoon SM; Song SY; Lee YS; Kim SB; Park SI; Ahn SD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):691-7. PubMed ID: 20888705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
    Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
    Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
    Motoori M; Yano M; Ishihara R; Yamamoto S; Kawaguchi Y; Tanaka K; Kishi K; Miyashiro I; Fujiwara Y; Shingai T; Noura S; Ohue M; Ohigashi H; Nakamura S; Ishikawa O
    Ann Surg Oncol; 2012 Jul; 19(7):2135-41. PubMed ID: 22302264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil.
    Sai H; Mitsumori M; Yamauchi C; Araki N; Okumura S; Nagata Y; Nishimura Y; Hiraoka M
    Int J Clin Oncol; 2004 Jun; 9(3):149-53. PubMed ID: 15221597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer.
    Yoo C; Park JH; Yoon DH; Park SI; Kim HR; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Kim YH; Kim SB
    Ann Thorac Surg; 2012 Dec; 94(6):1862-8. PubMed ID: 22959577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?
    Tougeron D; Scotté M; Hamidou H; Di Fiore F; Paillot B; Michot F; Michel P
    J Surg Oncol; 2012 Jun; 105(8):761-6. PubMed ID: 22124932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
    Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
    Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undernutrition is predictive of early mortality after palliative self-expanding metal stent insertion in patients with inoperable or recurrent esophageal cancer.
    Lecleire S; Di Fiore F; Antonietti M; Ben Soussan E; Hellot MF; Grigioni S; Déchelotte P; Lerebours E; Michel P; Ducrotté P
    Gastrointest Endosc; 2006 Oct; 64(4):479-84. PubMed ID: 16996335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma.
    Chao YK; Yeh CJ; Chang HK; Tseng CK; Chu YY; Hsieh MJ; Wu YC; Liu HP
    Ann Surg Oncol; 2011 Feb; 18(2):529-34. PubMed ID: 20697822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.
    Ishikura S; Nihei K; Ohtsu A; Boku N; Hironaka S; Mera K; Muto M; Ogino T; Yoshida S
    J Clin Oncol; 2003 Jul; 21(14):2697-702. PubMed ID: 12860946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
    Hsu FM; Lee JM; Huang PM; Lin CC; Hsu CH; Tsai YC; Lee YC; Chia-Hsien Cheng J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e593-9. PubMed ID: 21658851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
    Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
    Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A; Sia S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.